Why is Biogen Pharma falling/rising?

As of 15-Sep, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at 0.89, which reflects a decrease of 0.02 or 2.2%. The stock has underperformed its sector by 2.35% today and has fallen after two consecutive days of gains. It is trading below its moving averages across various time frames, indicating a bearish trend. Despite declaring positive results for the last two consecutive quarters, including the highest PBDIT, PBT, and PAT at Rs 1.34 crore, the stock's long-term fundamental strength is weak, as evidenced by a low average Return on Equity (ROE) of 2.43% and a poor EBIT to Interest ratio of 1.19. Additionally, the stock has generated a return of -32.06% over the past year, with profits declining by 11%, contributing to its current downward movement.
In the broader market context, Biogen Pharma's performance over the past week shows no change, while the benchmark Sensex has increased by 1.24%. Over the past month, Biogen's stock has decreased by 1.11%, contrasting with the Sensex's gain of 1.47%. Year-to-date, Biogen's stock has significantly underperformed, with a decline of 24.58% compared to the Sensex's increase of 4.67%. This stark contrast highlights the stock's struggles in a generally positive market environment, further emphasizing the challenges it faces in regaining investor confidence amidst its weak fundamentals.